Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily eye drops to treat glaucoma, a leading cause of blindness.
Patients with diabetic DED can experience inflammatory biomarker reductions and sign and symptom improvements with topical insulin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback